Spot-Scanning Proton Radiation Therapy for Pediatric Chordoma and Chondrosarcoma: Clinical Outcome of 26 Patients Treated at Paul Scherrer Institute

Rombi, Barbara; Ares, Carmen; Hug, Eugen B.; Schneider, R.; Goitein, Gudrun; Staab, Adrian; Albertini, Francesca; Bolsi, Alessandra; Lomax, Anthony; Timmermann, Beate

doi:10.1016/j.ijrobp.2013.02.026

Cited by 69 publications

(38 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies of tumours outside the cns-including skull base chordoma and chondrosarcoma 22,23 , uveal melanoma 23,24 , germ-cell tumours 25 , high-risk neuroblastoma 26,27 , parameningeal rhabdomyosarcoma 28 , bladder and prostate rhabdomyosarcoma 29 , other soft tissue sarcomas 30 , Ewing sarcoma 31 , and mediastinal Hodgkin lymphoma 32 -uniformly showed that pbt is well tolerated, with local control rates similar to or higher than those achieved with photon rt. Although planning studies and early clinical results are promising, long-term data supporting a clear advantage of pbt over photon rt are not yet available.…”

Section: Pediatricsmentioning

confidence: 99%

Recommendations for the Referral of Patients for Proton-Beam Therapy, an Alberta Health Services Report: A Model for Canada?

et al. 2014

View full text Add to dashboard Cite

able and willing to travel abroad to a proton facility. Commonly accepted indications for referral include chordoma and chondrosarcoma, intraocular melanoma, and solid tumours in children and adolescents who have the greatest risk for long-term sequelae. Current data do not provide sufficient evidence to recommend routine referral of patients with most head-and-neck, breast, lung, gastrointestinal tract, and pelvic cancers, including prostate cancer. It is recommended that all referrals be considered by a multidisciplinary team to select appropriate cases.

show abstract

Section: Pediatricsmentioning

confidence: 99%

Recommendations for the Referral of Patients for Proton-Beam Therapy, an Alberta Health Services Report: A Model for Canada?

et al. 2014

View full text Add to dashboard Cite

show abstract

“…GyE at 1.8 -2.0 GyE/Fr [11] [12] [13]. We have also obtained good local control for adult chordoma using PBT at 78.4 GyE in 56 fractions (2 fractions per day).…”

Section: Discussionmentioning

confidence: 84%

Preliminary Result of Hyperfractionated High-Dose Proton Beam Radiotherapy for Pediatric Skull Base Chordomas

Mizumoto¹,

Akutsu²,

Yamamoto³

et al. 2017

JCT

View full text Add to dashboard Cite

Objective: Proton beam therapy (PBT) may provide good local control for skull base chordoma and reduced toxicities, especially for pediatric patients. Methods: We evaluated the efficacy and safety of hyperfractionated high-dose PBT in6 pediatric patients with newly-diagnosed skull basechordoma who were treated with PBT at our institute from 2011 to 2015. The patients were 5 males and one female, and the median age was 9 years old (range: 5 -13). All patients received surgery before PBT. The median period between surgery and PBT was 57 days (range: 34 -129 days). The treatment dose was 78.4 GyE in 56 fractions (twice per day). Results: All patients received PBT without severe acute toxicity. The median follow-up period was 27 months (range: 21 -71 months). At the last follow-up, all patients were alive and all tumors were well controlled. Acute and late toxicities were generally acceptable, with only grade 1 and 2 events. Late toxicities included growth hormone abnormality and cortical hormone abnormality. One patient needed growth hormone and cortical hormone replacement therapy. Conclusion: Although the number of pediatric patients was small, our overall findings in the 6 cases indicate that hyperfractionated high-dose PBT is safe and effective for pediatric patients with skull base chordoma.

show abstract

“…PT has repeatedly demonstrated its ability to control this disease safely and more effectively than photon techniques at doses of 70-76 Gy (RBE) [47,48]. The most relevant data from the literature regarding clinical results after radiotherapy (protons or mixed photons and protons) for the treatment of chordomas and chondorsarcomas in pediatric patients are summarized in table 1 [49][50][51][52]. In the most recent study by Rombi et al [52] 26 patients were treated with spotscanning PT achieving 5-year LC of 81% and 80%, and 5-year OS rates of 89% and 75%, for chordomas and chondrosarcomas, respectively.…”

Section: Other Pediatric Malignancies Outside Cnsmentioning

confidence: 99%

“…The most relevant data from the literature regarding clinical results after radiotherapy (protons or mixed photons and protons) for the treatment of chordomas and chondorsarcomas in pediatric patients are summarized in table 1 [49][50][51][52]. In the most recent study by Rombi et al [52] 26 patients were treated with spotscanning PT achieving 5-year LC of 81% and 80%, and 5-year OS rates of 89% and 75%, for chordomas and chondrosarcomas, respectively. Furthermore, there were relatively few (19%) late complications and no high grade (≤ grade 2) late toxicities were noted.…”

Section: Other Pediatric Malignancies Outside Cnsmentioning

confidence: 99%

Proton Radiotherapy for Childhood Tumors: an Overview of Early Clinical Results

MacDonald¹

2013

J Nucl Med Radiat Ther

View full text Add to dashboard Cite

Radiation therapy (RT) is an important part of a multidisciplinary treatment for many pediatric tumors and has been integral to the improvement in disease control seen over the past few decades. However, long-term survivors experience late morbidity related to RT. Proton radiation therapy is an emerging type of radiotherapy that can mitigate the incidence of acute and late side effects by minimizing the dose of radiation to normal tissues with a significant reduction of integral dose compared with photons. Furthermore, true clinical advantages are now being measured and published in the medical literature, showing both excellent disease control rates and reduction of late effects. The purpose of this review is to summarize the early clinical outcomes after proton radiotherapy in childhood available in the literature.

show abstract

Spot-Scanning Proton Radiation Therapy for Pediatric Chordoma and Chondrosarcoma: Clinical Outcome of 26 Patients Treated at Paul Scherrer Institute

Cited by 69 publications

References 20 publications

Recommendations for the Referral of Patients for Proton-Beam Therapy, an Alberta Health Services Report: A Model for Canada?

Recommendations for the Referral of Patients for Proton-Beam Therapy, an Alberta Health Services Report: A Model for Canada?

Preliminary Result of Hyperfractionated High-Dose Proton Beam Radiotherapy for Pediatric Skull Base Chordomas

Proton Radiotherapy for Childhood Tumors: an Overview of Early Clinical Results

Contact Info

Product

Resources

About